Alfasigma: STAT+: Intercept, once a biotech trailblazer, sells itself for less than $1 billion

Intercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the hottest stock in biotech, said it would sell the company for less than $1 billion.